by Cathryn Donaldson
July 31, 2018
WASHINGTON, D.C. – America’s Health Insurance Plans (AHIP) issued the following statement following the Centers for Medicare and Medicaid Services (CMS) announcement that Medicare Part D premiums continue to decline in 2019:
“When it comes to prescription drugs, the problem is the price. And prices for branded drugs are out of control and out of reach for many Americans who need them.
However, when Congress required manufacturers to give bigger discounts on branded drugs for seniors in the 2018 Bipartisan Budget Act (BBA), it lowered costs for both seniors and hardworking taxpayers. This afternoon CMS announced that 2019 Part D premiums are declining, reaffirming that the Part D coverage gap or ‘donut hole’ drug discounts save money for patients. The changes made in the BBA lower premiums for Medicare beneficiaries, increase manufacturer discounts for brand name drugs in the donut hole, and extend discounts to “biosimilar” versions of high priced biotech drugs.
Despite aggressive efforts by the pharmaceutical industry to reverse these changes, we urge Congress to continue to resist efforts to undo these new provisions and protect seniors’ affordable access to the care they need.”